期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他汀类药物与氯吡格雷相互作用争议的现状 被引量：20

暂未订购
导出
摘要 近年来大规模随机试验证实,他汀类药物具有多效性,在冠心病的一级和二级预防中具有肯定的效果,并且强化他汀类药物的治疗在急性冠脉综合征(ACS)和经皮冠脉介入治疗(PCI)中有重要价值。阿司匹林联合应用氯吡格雷能进一步减少ACS和PCI患者的血栓并发症。临床上已经将强化他汀类药物和双重抗血小板治疗应用于ACS和PCI患者,并取得了较理想的效果。但一些小样本研究提示他汀类药物和氯吡格雷合用竞争肝细胞色素P450同工酶CYP3A4而降低氯吡格雷抗血小板的能力,但多数研究显示,阿托伐他汀等经CYP3A4代谢的他汀和氯吡格雷同时使用并不降低氯毗格雷的抗血小板作用。该文就他汀类药物与氯吡格雷相互作用的争议进行综述。
作者 王燕慧 张灏
机构地区 甘肃省第二人民医院重症监护室 甘肃省第二人民医院心内科
出处 《国际心血管病杂志》 2011年第2期104-107,共4页 International Journal of Cardiovascular Disease
关键词 氯吡格雷 他汀类药物 肝细胞色素P450 急性冠脉综合征 经皮冠状动脉介入治疗
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献26

  • 1Lau WC, Waskell LA, Watkins PB,et al. Atorvastafin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction[J]. Circulation, 2003,107 ( 1 ) : 32-37.
  • 2Faxon DP, Nesto RW. Antiplatelet therapy in populations at high risk of atherothromhosis[J]. J Natl Med Assoc,2006,98 (5) :711-721.
  • 3Wenger NK, Lewis SJ, Herrington DM, et al . Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease [ J ]. Ann Intern Med, 2007,147 ( 1 ) :1-9.
  • 4Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial [J]. J Am Coll Cardiol, 2007,49(12) : 1272-1278.
  • 5Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated Creactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial [J]. Ann Intern Med, 2010,152(8):488-496.
  • 6Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI PROVE IT: A PROVE IT TIMI 22 ( Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy [J]. J AmCollCardiol, 2009,54(24):2290-2295.
  • 7Mora S, Glynn RJ, Hsia J, et al. Statins Yor the primary prevention of cardiovascular events in women with elevated high sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta analysis of women from primary prevention trials[J]. Circulation, 2010,121(9) :1069 -1077.
  • 8Ridker PM, MacFadyen J, Cressman M, et aI. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high sensitivity C-reactive protein : a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial[J].J Am Coil Cardiol, 2010,55(12) : 1266-1273.
  • 9Everett BM, Glynn RJ, MacFadyen JG, et al. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)[J].Circulation, 2010, 121 (1) 143-150.
  • 10Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta analysis of randomised statin trials[J]. Lancet, 2010,375(9716) :735- 742.

同被引文献257

  • 1Hovens MM,Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin., a systemat- ic review. Am Heart J,2007,153:175-181.
  • 2Ainetdinova DKH, Udovichenko AE, Sulimov VA. Resistance to antipIatelet drugs in patients with non ST elevation acute coronary syndrome. Kardiologiia, 2008,48 : 35-39.
  • 3Nguyen TA,Diodati IG,Pharand C,et al. Resistance to clopi- dogrel:a review of the evidence. J Am Coll Cardiol, 2005, 1945:1157-1164.
  • 4Ho PM,Maddox MT, Wang L, et al. Risk of adverse out- comes associated with concomitant use of clopidogre and pro- ton pump inhibitors following acute coronary syndrome. JAMA,2009,301 :937-944.
  • 5Juurlink DN,Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009,180 : 699-700.
  • 6Gilard M,Amaud B, Comily JC, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated with aspirin the randomized double hlind OCLA(Omeprazole Clopidogrel Aspirin) study. J Am Coil Cardiol,2008,51:256-260.
  • 7Pezalla E,Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coil Cardiol, 2008,52 : 1037 1039.
  • 8Aubert RE, Epstein RS, Teagarden JR, el al. Proton Pump In- hibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medeo Outcomes Study. Circulation, 2008,118 : 815.
  • 9Cuissel T, Frere C, Quiliei J, el al. Comparison of omeprazole and pantoprazole influence on a high 150rag clopidogrel main- tenance dose the PACA(Proton Pump Inhibitors And Clopi dogrel Association) prospective randomized study. J Am Coll Cardiol, 2009,54 : 1149-1153.
  • 10Vlachojannis GJ,Dimitropoulos G, Alexopoulos D. Clopidogrel re sistance: current aspects and future directions[J]. Hellenic J Car diol,2011,52(3) ：236-245.

引证文献20

二级引证文献156

国际心血管病杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部